ALKS Alkermes plc

NASDAQ
$46.85

Alkermes plc (ALKS) is expected to report earnings on February 2, 2027, before the market open. The consensus earnings estimate is a loss of $0.24 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.5% since its last earnings release on November 3, 2026.

Alkermes plc Beat Consensus Estimates, Reaffirms
Tuesday, November 3, 2026 · 7:05 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 7:05 AM ET
Earnings Whisper
-
vs ($0.24)
Rev est $457.06M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $46.18

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Alkermes plc

Alkermes PLC is a biotechnology company engaged in developing, manufacturing & commercializing medicines. The Company has a portfolio of commercial drug products & a clinical pipeline of product candidates that address central nervous system disorders.

Sector

Healthcare

Industry

Drug Manufacturers/Other

Charts powered in part by Lightweight Charts™ by TradingView.